Healthpeak Properties is a Denver-based healthcare real estate investment trust that owns, operates, and develops properties at the intersection of healthcare discovery and outpatient care delivery. Founded in 1985 as Healthcare Property Investors and rebranded as Healthpeak Properties in 2019, the REIT operates under the NYSE ticker symbol DOC, which reflects its strategic focus on "Discovery and Outpatient Care." The company is a constituent of the S&P 500 index. The REIT's investment strategy centers on specialized real estate that supports the full continuum of care. Its lab properties house life science tenants developing therapeutics, diagnostics, and medical devices in leading innovation clusters. Its outpatient medical buildings, predominantly located on or near hospital campuses, provide convenient access to physician specialists and healthcare services. The company also maintains a portfolio of continuing care retirement communities that serve seniors through resident-fee and entrance-fee models. In March 2024, Healthpeak completed a merger with Physicians Realty Trust, which expanded its outpatient medical platform and prompted the adoption of the DOC ticker symbol. This combination positioned the company as a major owner of outpatient medical real estate while preserving its exposure to life science properties in coastal innovation hubs. The company maintains investment-grade credit ratings of BBB+/Baa1, supporting its access to capital markets across economic cycles. Healthpeak's lab portfolio is concentrated in high-barrier markets including San Francisco, Boston, and San Diego, where biopharma and academic demand clusters around research ecosystems and talent. The outpatient medical segment focuses on properties affiliated with health systems and positioned near hospital campuses, benefiting from physician proximity requirements and patient convenience. The company has scaled its South San Francisco footprint through strategic acquisitions, building a campus-oriented presence in one of the nation's most active life science markets. The company pursues a capital allocation strategy that balances portfolio recycling with selective growth opportunities. Recent activity includes disposing of stabilized outpatient medical assets at attractive valuations and redeploying capital into strategic life science acquisitions with lease-up potential. Leadership emphasizes platform capabilities, tenant relationships, and market positioning as competitive advantages in both segments.